(Q40873283)

13 June 2018

title

Aspirin use and the risk of cholangiocarcinoma (English)

1 reference

13 June 2018

0 references

1 reference

10

1 reference

13 June 2018

William Scott Harmsen

6

object named as

William S Harmsen

1 reference

13 June 2018

author name string

Jonggi Choi

1

1 reference

13 June 2018

Hassan M Ghoz

2

1 reference

13 June 2018

Thoetchai Peeraphatdit

3

1 reference

13 June 2018

Esha Baichoo

4

1 reference

13 June 2018

Benyam D Addissie

5

1 reference

13 June 2018

Terry M Therneau

7

1 reference

13 June 2018

Janet E Olson

8

1 reference

13 June 2018

Roongruedee Chaiteerakij

9

1 reference

13 June 2018

language of work or name

English

0 references

publication date

26 April 2016

1 reference

13 June 2018

published in

Hepatology

1 reference

13 June 2018

volume

64

1 reference

13 June 2018

issue

3

1 reference

13 June 2018

page(s)

785-796

1 reference

13 June 2018

Aspirin use among adults in the U.S.: results of a national survey.

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

17 June 2018

Hilar cholangiocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

The Mayo Clinic Biobank: a building block for individualized medicine

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Risk factors for cholangiocarcinoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Aspirin, salicylates, and cancer.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

The antecedents of biliary cancer: a primary care case-control study in the United Kingdom.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Aspirin dose and duration of use and risk of colorectal cancer in men.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Aspirin use among adults aged 40 and older in the United States: results of a national survey

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Aspirin use and risk of biliary tract cancer: a population-based study in Shanghai, China

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Genomic Instability and Cancer

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Time-window bias in case-control studies: statins and lung cancer.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Effects of selective COX-inhibitors and classical NSAIDs on endothelial cell proliferation and migration induced by human cholangiocarcinoma cell culture.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5995727

Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: A nationwide case-control study

19 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FHEP.28529

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26940227

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cyclooxygenase-2 inhibitors in tumorigenesis (part I)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26940227

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/HEP.28529

1 reference

13 June 2018

PMCID

5995727

1 reference

13 June 2018

PubMed ID

26940227

1 reference

13 June 2018